Research has shown that elevated levels of C5a have been associated with pathogenesis of a variety of disease states including myocardial infarction, stroke and kidney injury. The role of C5a in the pathogenesis of malaria and other infectious diseases as well as sepsis is likewise well documented.

The MicroVue C5a Enzyme Immuno***** measures the concentration of C5a in human plasma, serum and other experimental samples. It uses a proprietary monoclonal antibody to a neo-epitope on C5a to capture C5a in solid phase. The trapped C5a is then detected by HRP-labeled antibodies to C5a antigens. This test provides a quantitative measurement of C5a levels and is designed for investigations into the role and status of terminal complement pathway activation in numerous clinical and research settings.